Related Initiatives
|
|
|
Related InitiativesNCI research initiatives in cancer genomics, epigenomics, proteomics, and nanotechnology depend on the development of new sources of high-quality human biospecimens and the identification of appropriate biospecimens in existing resources. Human biospecimens are essential resources to accelerate the development of molecular-based diagnostics and therapeutics for personalized medicine. High-quality, clinically annotated human biospecimens are essential resources for the research needed to:
Information gathered by the NCI has identified a significant lack of standards in the methods used to collect, process, store, and disseminate biospecimens. These lack of standards may affect the outcomes of molecular research initiatives across the cancer research enterprise. The BBRB works with research programs across the NCI to improve biospecimen resources and to establish new high-quality resources. These research programs include large-scale genomic and proteomic studies that require sufficient numbers of quality-controlled biospecimens to enable reproducible, statistically significant comparisons of control and research subject samples, such as:
The BBRB assists with biospecimen issues challenging other key initiatives such as: |